Incara’s proposed treatment to protect healthy cells from cancer radiation treatment while at the same time hindering growth of cancer cells is headed for a second phase of study.

Incara (OTC Bulletin Board: ICRA) said Thursday that it would receive $375,000 a Small Business Innovation Research Grant from the National Cancer Institute. Another $375,000 has been approved for a third year as well.

“Pre-clinical studies have found that compounds from Incara’s antioxidant program have protected normal cells during animal models of radiation therapy as well as inhibited the growth of tumors in animal models of cancer,” Incara said in a statement.

One Incara compound, AEOL 10113, has been selected for the second phase of study.

Incara is working with Duke University Medical Center and the Department of Radiation Oncology at Duke University Medical Center.

Richard Gammans, PhD, is principal investigator. He is head of research and development at Incara. Zeljko Vujaskovic, an MD and PhD, is the designated collaborator from Duke. He is an associate clinical professor of radiation oncology.

Incara’s research stems from work done by former Duke professors.

Incara is also pursing development of treatments for Lou Gehrig’s Disease and stroke.

Incara: www.incara.com